ArticleBlood advances2018
Recurrent
Open access · goldAbstract read
In one paragraph
Article in Blood advances, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 28 citations in OpenAlex.
- Age-specific mutation profiles and their prognostic implications in pediatricHaematologica · 2026Article
- Research Progress on the KMT2A-AFF3 Fusion Gene in Childhood Acute Lymphoblastic Leukemia: Mechanisms, Clinical Implications, and Therapeutic Strategies.Current issues in molecular biology · 2025Review
- Analysis and Interpretation of Somatic NMD-Escaping Variants in Oncogenes and Dual-Function Genes across Adult and Pediatric Cancer Cohorts.medRxiv : the preprint server for health sciences · 2025Article
- The genomic landscape of relapsed infant and childhood KMT2A-rearranged acute leukemia.Nature communications · 2025Article
- Network-based analysis and experimental validation of identified natural compounds from Yinchen Wuling San for acute myeloid leukemia.Frontiers in pharmacology · 2025Article
- KRAS G12 mutations as adverse prognostic factors in KMT2A-rearranged acute myeloid leukemia.Leukemia · 2024Article
- Somatic evolution of marine transmissible leukemias in the common cockle, Cerastoderma edule.Nature cancer · 2023Article
- Complete miRNA-15/16 loss in mice promotes hematopoietic progenitor expansion and a myeloid-biased hyperproliferative state.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Genome-wide DNA methylation analysis in pediatric acute myeloid leukemia.Blood advances · 2022Article
- Clinical significance of RAS pathway alterations in pediatric acute myeloid leukemia.Haematologica · 2022Article
- Clinical profile inFrontiers in medicine · 2022Article
- Efficacy of a combination therapy targeting CDK4/6 and autophagy in a mouse xenograft model of t(8;21) acute myeloid leukemia.Biochemistry and biophysics reports · 2021Article
- Recurrent Mutations in Cyclin D3 Confer Clinical Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021Article
- Review
- The RUNX1/RUNX1T1 network: translating insights into therapeutic options.Experimental hematology · 2021Review
- Inhibition of CDK4/6 and autophagy synergistically induces apoptosis in t(8;21) acute myeloid leukemia cells.International journal of hematology · 2021Article
- Landscape of driver mutations and their clinical impacts in pediatric B-cell precursor acute lymphoblastic leukemia.Blood advances · 2020Article
- Fusion partner-specific mutation profiles and KRAS mutations as adverse prognostic factors in MLL-rearranged AML.Blood advances · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
38 authors at 17 institutions in 3 countries.
Hidemasa MatsuoDepartment of Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID 0000-0002-7578-006X
Kenichi YoshidaDepartment of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Kazutaka FukumuraDepartment of Cellular Signaling, Graduate School of Medicine.
Kana NakataniDepartment of Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Yuki NoguchiDepartment of Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Saho TakasakiDepartment of Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Mina NouraDepartment of Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Yusuke ShiozawaDepartment of Pediatrics, and.
Yuichi ShiraishiLaboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Kenichi ChibaLaboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Hiroko TanakaLaboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Ai OkadaLaboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Yasuhito NannyaDepartment of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
June TakedaDepartment of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Hiroo UenoDepartment of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Norio ShibaDepartment of Hematology/Oncology, Gunma Children's Medical Center, Gunma, Japan.
Genki YamatoDepartment of Hematology/Oncology, Gunma Children's Medical Center, Gunma, Japan.
Hiroshi HandaDepartment of Hematology, Gunma University Graduate School of Medicine, Gunma, Japan.
Yuichiro OnoDepartment of Hematology, Kobe City Medical Center General Hospital, Kobe, Japan.
Nobuhiro HiramotoDepartment of Hematology, Kobe City Medical Center General Hospital, Kobe, Japan.
Takayuki IshikawaDepartment of Hematology, Kobe City Medical Center General Hospital, Kobe, Japan.
Kensuke UsukiDepartment of Hematology, NTT Medical Center, Tokyo, Japan.
Ken IshiyamaDivision of Hematology, Tokyo Metropolitan Ohtsuka Hospital, Tokyo, Japan.
Shuichi MiyawakiDivision of Hematology, Tokyo Metropolitan Ohtsuka Hospital, Tokyo, Japan.
Hidehiro ItonagaDepartment of Hematology, Atomic Bomb Disease and Hibakusya Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan.
Yasushi MiyazakiDepartment of Hematology, Atomic Bomb Disease and Hibakusya Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan.
Machiko KawamuraDepartment of Hematology, Saitama Cancer Center, Saitama, Japan.
Hiroki YamaguchiDepartment of Hematology, Nippon Medical School, Tokyo, Japan.
Nobutaka KiyokawaDepartment of Pediatric Hematology and Oncology Research, National Research Institute for Child Health and Development, Tokyo, Japan.
Daisuke TomizawaDivision of Leukemia and Lymphoma, Children's Cancer Center, National Center for Child Health and Development, Tokyo, Japan.ORCID 0000-0003-1520-7007
Takashi TagaDepartment of Pediatrics, Shiga University of Medical Science, Otsu, Japan.
Akio TawaDepartment of Pediatrics, Osaka National Hospital, Osaka, Japan; and.
Yasuhide HayashiDepartment of Hematology/Oncology, Gunma Children's Medical Center, Gunma, Japan.
Hiroyuki ManoDepartment of Cellular Signaling, Graduate School of Medicine.
Satoru MiyanoLaboratory of DNA Information Analysis, Human Genome Center, Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Yasuhiko KamikuboDepartment of Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Seishi OgawaDepartment of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Souichi AdachiDepartment of Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Kyoto University · JPThe University of Tokyo · JPKobe City Medical Center General Hospital · JPNagasaki University · JPNational Center For Child Health and Development · JPTokyo Metropolitan Ohtsuka Hospital · JPToxicologie, Pharmacologie et Signalisation Cellulaire · FRGunma Children's Medical Center · JPGunma University · JPJapanese Red Cross Society, Japan · JPNippon Medical School · JPNTT Medical Center · JPOsaka National Hospital · JPPediatrics and Genetics · USSaitama Cancer Center · JPShiga University of Medical Science · JPYokohama City University Hospital · JP
Funding
No grant is acknowledged in the PubMed record.
Abstract
In acute myeloid leukemia (AML),
Indexed as
AdolescentChildChild, PreschoolCyclin DCyclin D3DNA Copy Number VariationsFemaleG1 Phase Cell Cycle CheckpointsGene RearrangementHistone-Lysine N-MethyltransferaseHumansInfantInfant, NewbornLeukemia, Myeloid, AcuteMaleMutationCCND3 protein, humanCyclin DCyclin D3Histone-Lysine N-MethyltransferaseKMT2A protein, humanMyeloid-Lymphoid Leukemia ProteinProtein Kinase InhibitorsRNA, Small Interfering
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.